Stay updated on Milademetan Safety in AML/MDS Clinical Trial
Sign up to get notified when there's something new on the Milademetan Safety in AML/MDS Clinical Trial page.

Latest updates to the Milademetan Safety in AML/MDS Clinical Trial page
- Check6 days agoChange DetectedThe page shows a new revision label: v3.3.2 replacing v3.3.1, a minor technical update that does not affect the study information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check13 days agoChange DetectedThe page now displays an updated revision banner: Revision v3.3.1 replaces Revision v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check20 days agoChange DetectedRemoved the general government funding update notice from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check34 days agoChange DetectedThere are no substantive changes to the study content; only minor cosmetic and layout adjustments are visible across sections. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check63 days agoChange DetectedCore clinical content (the disease name) was removed; a new version tag (v3.2.0) and an operational status notice were added, signaling a page update and potential deprecation of the previous content.SummaryDifference2%

- Check70 days agoChange DetectedPage revision updated from v3.0.2 to v3.1.0, indicating a version bump with no other substantive content changes.SummaryDifference0.1%

Stay in the know with updates to Milademetan Safety in AML/MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Milademetan Safety in AML/MDS Clinical Trial page.